텔러미어 파머슈티컬스(TELO)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.23 (+9.82%), 시가총액 $81.84M, 52주 범위 $1.08 ~ $2.29.
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc.
텔러미어 파머슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
텔러미어 파머슈티컬스의 현재 주가는 $1.23 (+9.82%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
텔러미어 파머슈티컬스의 시가총액은 약 $81.84M입니다.
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and…